29 November 2024
We are pleased to announce that CVC has officially acquired the Therakos company from Mallinckrodt Pharmaceuticals, marking an exciting new era for the Therakos company. This strategic acquisition underscores CVC’s commitment to advancing innovative healthcare solutions and supporting the continued growth of the Therakos company.  During the transition period, certain systems and processes will remain managed by Mallinckrodt under a Transition Services Agreement (TSA) to ensure a smooth handover. We remain focused on maintaining uninterrupted service and support for all stakeholders throughout this process.  Thank you for your continued support during this transition.